These criteria guide both diagnostic classification and long-term treatment strategies, given the neuroadaptive changes that increase vulnerability to relapse
In this subpopulation, at baseline, 85% of patients were treated with ACE inhibitor or ARB, 79% with statins, and 48% with antiplatelet agents
Built for you How Shotsy fits into care Can be used alongside clinical care Patients may choose to share tracked data with clinicians Does not replace visits or clinical monitoring FEATURES Everything you need, in one place
Hormonal Disruption: The postpartum period is already full of significant hormonal shifts that impact metabolism, mood, and appetite

Cash Pay Options Manufacturer Direct Programs: Novo Nordisk: $199/month for first two doses, then $349/month Eli Lilly LillyDirect: $299-$499/month depending on dose TrumpRx Platform (Launching Early 2026): Injectable GLP-1s: $350/month initially, dropping to $250 within 2 years Oral GLP-1s (pending FDA approval): $149/month for starting doses GoodRx/Discount Cards: Prices vary by pharmacy and location Typically $900-$1,200/month without manufacturer programs Check current prices at your local Hinsdale pharmacies Cost Comparison: What You'll Actually Pay Ozempic (semaglutide for diabetes): Insurance copay: $25-$100/month Medicare (2026): $50/month Cash (manufacturer direct): $199-$349/month List price: $969/month Wegovy (semaglutide for obesity): Insurance copay: Often not covered Medicare (2026): $50/month Cash (manufacturer direct): $199-$349/month List price: $1,349/month Mounjaro (tirzepatide for diabetes): Insurance copay: $25-$100/month Medicare (2026): $50/month List price: $1,069/month Zepbound (tirzepatide for obesity): Insurance copay: Often not covered Medicare (2026): $50/month Cash (manufacturer direct): $299-$499/month List price: $1,059/month At Well Endocrinology, we help patients navigate insurance coverage, prior authorizations, and manufacturer savings programs to minimize out-of-pocket costs
